Jenny C. Yang

5.5k total citations
24 papers, 1.0k citations indexed

About

Jenny C. Yang is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Jenny C. Yang has authored 24 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Epidemiology, 17 papers in Hepatology and 7 papers in Infectious Diseases. Recurrent topics in Jenny C. Yang's work include Hepatitis C virus research (17 papers), Hepatitis B Virus Studies (15 papers) and Liver Disease Diagnosis and Treatment (11 papers). Jenny C. Yang is often cited by papers focused on Hepatitis C virus research (17 papers), Hepatitis B Virus Studies (15 papers) and Liver Disease Diagnosis and Treatment (11 papers). Jenny C. Yang collaborates with scholars based in United States, Taiwan and New Zealand. Jenny C. Yang's co-authors include Brian T. Tsuji, Jürgen B. Bulitta, Neang S. Ly, Alan Forrest, Anthony Jarkowski, Dana R. Anderson, Lauren Lim, William J. Jusko, John G. McHutchison and Phillip S. Pang and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.

In The Last Decade

Jenny C. Yang

24 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jenny C. Yang United States	16	565	441	410	283	130	24	1.0k
Frédéric Bert France	17	449 0.8×	340 0.8×	225 0.5×	139 0.5×	138 1.1×	36	1.2k
M.‐H. Nicolas‐Chanoine France	11	643 1.1×	636 1.4×	347 0.8×	108 0.4×	117 0.9×	18	1.2k
Chiara Simona Cardellino Italy	11	306 0.5×	540 1.2×	131 0.3×	269 1.0×	67 0.5×	19	878
N. Mangeney France	11	383 0.7×	238 0.5×	198 0.5×	57 0.2×	95 0.7×	17	748
Myrto Christofidou Greece	18	342 0.6×	411 0.9×	68 0.2×	163 0.6×	119 0.9×	40	836
Zi-Ke Sheng China	15	167 0.3×	505 1.1×	53 0.1×	138 0.5×	168 1.3×	32	802
Belén Viñado Spain	16	565 1.0×	120 0.3×	322 0.8×	65 0.2×	202 1.6×	36	959
Alessia Carnelutti Italy	16	325 0.6×	229 0.5×	41 0.1×	125 0.4×	118 0.9×	42	833
Canan Külah Türkiye	16	174 0.3×	220 0.5×	36 0.1×	84 0.3×	112 0.9×	37	582
Hadir A. El‐Mahallawy Egypt	21	345 0.6×	511 1.2×	26 0.1×	133 0.5×	172 1.3×	53	1.1k

Countries citing papers authored by Jenny C. Yang

Since Specialization

Citations

This map shows the geographic impact of Jenny C. Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jenny C. Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jenny C. Yang more than expected).

Fields of papers citing papers by Jenny C. Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jenny C. Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jenny C. Yang. The network helps show where Jenny C. Yang may publish in the future.

Co-authorship network of co-authors of Jenny C. Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Jenny C. Yang. A scholar is included among the top collaborators of Jenny C. Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jenny C. Yang. Jenny C. Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gane, Edward, P. Rod Dunbar, Anna E. S. Brooks, et al.. (2022). Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression. Journal of Hepatology. 78(3). 513–523. 25 indexed citations

Burdette, Dara, Scott E. Lazerwith, Jenny C. Yang, et al.. (2022). Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy. PLoS ONE. 17(4). e0262516–e0262516. 8 indexed citations

Yang, Jenny C., et al.. (2020). Molecular epidemiology of Pseudomonas aeruginosa isolated from lower respiratory tract of ICU patients. Brazilian Journal of Biology. 81(2). 351–360. 9 indexed citations

Lok, Anna S., Fabien Zoulim, Geoffrey Dusheiko, et al.. (2019). Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. Hepatology Communications. 4(1). 8–20. 42 indexed citations

Wei, Lai, Masao Omata, Young‐Suk Lim, et al.. (2018). HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. Antiviral Research. 158. 178–184. 15 indexed citations

Wong, Robert J., Huy N. Trinh, Huy Nguyen, et al.. (2017). Significant Hepatic Fibrosis Among Treatment-Naive Chronic Hepatitis B Virus With Increased Hepatitis B Virus DNA and Normal Alanine Aminotransferase. Clinical Gastroenterology and Hepatology. 16(1). 146–148. 2 indexed citations

Mo, Hongmei, Charlotte Hedskog, Eric Lawitz, et al.. (2017). Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. Antiviral Research. 140. 151–157. 4 indexed citations

Lawitz, Eric, Jenny C. Yang, Luisa M. Stamm, et al.. (2017). Characterization of HCV Resistance from a 3-Day Monotherapy Study of Voxilaprevir, a Novel Pangenotypic NS3/4A Protease Inhibitor. Antiviral Therapy. 23(4). 325–334. 20 indexed citations

Kao, Jia‐Horng, Rong‐Nan Chien, Ting‐Tsung Chang, et al.. (2016). A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver International. 36(8). 1101–1107. 22 indexed citations

10.

Chuang, Wan‐Long, Rong‐Nan Chien, Cheng‐Yuan Peng, et al.. (2016). Ledipasvir/sofosbuvir fixed‐dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. Journal of Gastroenterology and Hepatology. 31(7). 1323–1329. 22 indexed citations

11.

Cooper, Curtis, Susanna Naggie, Michael S. Saag, et al.. (2016). Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir: Table 1.. Clinical Infectious Diseases. 63(4). 528–531. 13 indexed citations

12.

Wilder, Julius, Lennox J. Jeffers, Natarajan Ravendhran, et al.. (2015). Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Hepatology. 63(2). 437–444. 49 indexed citations

13.

Alqahtani, Saleh A., Nezam H. Afdhal, Stefan Zeuzem, et al.. (2015). Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology. 62(1). 25–30. 68 indexed citations

14.

Ly, Neang S., Jenny C. Yang, Jürgen B. Bulitta, & Brian T. Tsuji. (2012). Impact of Two-Component Regulatory Systems PhoP-PhoQ and PmrA-PmrB on Colistin Pharmacodynamics in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 56(6). 3453–3456. 24 indexed citations

15.

Lawitz, Eric, John M. Hill, Thomas Marbury, et al.. (2012). A Phase I, Randomized, Placebo-Controlled, 3-Day, Ascending-Dose Study of Gs-9451, An Ns3/4A Protease Inhibitor, in Genotype 1 Hepatitis C Patients. Antiviral Therapy. 18(3). 311–319. 8 indexed citations

16.

Ting, Lillian, Jens Præstgaard, Nicole Grunenberg, et al.. (2012). A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study To Assess the Safety and Tolerability of LFF571 in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 56(11). 5946–5951. 27 indexed citations

17.

Bulitta, Jürgen B., Jenny C. Yang, Neang S. Ly, et al.. (2010). Attenuation of Colistin Bactericidal Activity by High Inoculum ofPseudomonas aeruginosaCharacterized by a New Mechanism-Based Population Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy. 54(5). 2051–2062. 106 indexed citations

18.

Lim, Lauren, Neang S. Ly, Dana R. Anderson, et al.. (2010). Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(12). 1279–1291. 339 indexed citations

19.

Bulitta, Jürgen B., Neang S. Ly, Jenny C. Yang, et al.. (2008). Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 53(1). 46–56. 78 indexed citations

20.

Yang, Jenny C., Brian T. Tsuji, & Alan Forrest. (2007). Optimizing Use of Quinolones in the Critically Ill. Seminars in Respiratory and Critical Care Medicine. 28(6). 586–595. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact